Gufic BioScience
Drug Manufacturers - Specialty & Generic · GUFICBIO
Small CapHealthcareHigh Growth
Jayesh P. Choksi
Chairman & Managing Director · Visionary
Company DNA
Founder-Centric
About
Gufic BioScience is a Small Cap company in the Healthcare sector, listed on NSE as GUFICBIO. With a market cap of ₹3K Cr and revenue of ₹746 Cr, it is currently in the High Growth phase. Known for its Founder-Centric culture and Disruptor approach to innovation, the company operates at a Startup-Speed pace. High promoter holding (77.5%) and active management by the Chairman indicates a top-down culture driven by founding family vision. Its strategic mandate: Transitioning from niche pharma to a broader specialty player requires R&D investment and portfolio transformation to capture market share.
FAQ
What kind of company is Gufic BioScience?
Gufic BioScience is a Small Cap Healthcare company (GUFICBIO) in the High Growth phase with a market cap of ₹3K Cr. It is classified as Founder-Centric in culture.
What is Gufic BioScience's culture and work environment like?
Gufic BioScience has a Founder-Centric culture with Disruptor innovation DNA and a Startup-Speed pace of execution. Employee brand: Learning Ground. Customer relationship style: B2B-Enterprise. High promoter holding (77.5%) and active management by the Chairman indicates a top-down culture driven by founding family vision.
Who leads Gufic BioScience?
Gufic BioScience is led by Jayesh P. Choksi (Chairman & Managing Director), a Visionary leader with 25 years of experience.
What are Gufic BioScience's financials?
Gufic BioScience reported revenue of ₹746 Cr in FY25 with a 5-year revenue CAGR of 1.5%. Operating margin: 15.7%. Market cap: ₹3K Cr.
Culture & Strategy
CultureFounder-Centric
InnovationDisruptor
PaceStartup-Speed
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployeeLearning Ground
BrandTechnical-Expert
LifecycleHigh Growth
High promoter holding (77.5%) and active management by the Chairman indicates a top-down culture driven by founding family vision.
Mandate
Transitioning from niche pharma to a broader specialty player requires R&D investment and portfolio transformation to capture market share.
Transitioning from niche pharma to a broader specialty player requires R&D investment and portfolio transformation to capture market share.
Financials
Revenue FY25₹746 Cr
PAT FY25₹70 Cr
Rev CAGR 5Y1.5%
OPM15.7%
NPM9.3%
ROE11.6%
ROCE15%
P/E57.8
Fwd P/E—
P/B4.6
D/E58.5
Mkt Cap₹3K Cr
Promoter77.5%
Institutional3.6%
Similar Culture
Could You Lead Gufic BioScience?
Take the Genome Benchmark →